Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

Rhea-AI Summary

Aeterna Zentaris Inc. announced that its CEO, Dr. Klaus Paulini, will participate in the Virtual Investor Ask the CEO Conference on October 25th. Investors can submit questions live or pre-submit them through the event's website. The presentation will be available for replay on the company's website.

Positive

• None.

Negative

• No concrete business takes were found in the PR.

– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25^th at 10:00 AM ET

TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 10:00 AM ET.

The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through virtualinvestorco.com/asktheceo-aezs. Participating companies will answer as many questions as possible during the event.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.zentaris.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen^®; Ghryvelin^™), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

Aeterna Zentaris is dedicated to the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com

FAQ

What is the Virtual Investor Ask the CEO Conference?

The Virtual Investor Ask the CEO Conference is an event where investors can ask questions directly to the management of participating companies.

When will the conference take place?

The conference will take place on October 25th.

How can investors submit questions?

Investors can submit questions live during the event or pre-submit them through the event's website.

Where can I watch the presentation?

The presentation will be available on the Events page of Aeterna Zentaris Inc.'s website.

Will there be a replay of the presentation?

Yes, a webcast replay will be available on the company's website.